Subscribe To
CC / Chemours: Time To Revisit And It's A 'Buy'
CC News
By Seeking Alpha
October 27, 2023
The Chemours Company (CC) Q3 2023 Earnings Call Transcript
The Chemours Company (NYSE:CC ) Q3 2023 Earnings Conference Call October 27, 2023 8:00 AM ET Company Participants Brandon Ontjes - Vice President of F more_horizontal
By Zacks Investment Research
October 26, 2023
Compared to Estimates, Chemours (CC) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended September 2023, it could be w more_horizontal
By Zacks Investment Research
October 23, 2023
Why Chemours (CC) Could Beat Earnings Estimates Again
Chemours (CC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat i more_horizontal
By Business Wire
October 6, 2023
Chemours Announces Dates for Third Quarter 2023 Earnings Release and Webcast Conference Call
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Announces Dates for Third Quarter 2023 Earnings Release and Webcast Conference Call. more_horizontal
By Zacks Investment Research
September 27, 2023
Here's Why You Should Hold Onto Chemours (CC) Stock For Now
Chemours (CC) gains on strong execution, continued Opteon adoption and its efforts to reduce costs amid headwinds from demand weakness. more_horizontal
By Reuters
September 27, 2023
Dutch court rules Chemours liable for environmental damage caused by PFAS
U.S. chemical company Chemours CC.N is liable for environmental damage in the Netherlands caused by PFAS chemicals, the Rotterdam District Court ruled more_horizontal
By Zacks Investment Research
August 31, 2023
Chemours (CC) Benefits From Opteon Adoption Amid Demand Woes
Although Chemours (CC) is being challenged by softer demand in certain businesses, it gains on continued Opteon adoption, strong execution and its cos more_horizontal
By Zacks Investment Research
August 22, 2023
Here's Why You Should Retain Chemours (CC) in Your Portfolio
While Chemours (CC) is exposed to headwinds from demand softness in certain areas, it gains on continued Opteon adoption, strong execution and its cos more_horizontal